WO2005025623A3 - Ef-24-factor vii conjugates - Google Patents
Ef-24-factor vii conjugates Download PDFInfo
- Publication number
- WO2005025623A3 WO2005025623A3 PCT/US2004/024490 US2004024490W WO2005025623A3 WO 2005025623 A3 WO2005025623 A3 WO 2005025623A3 US 2004024490 W US2004024490 W US 2004024490W WO 2005025623 A3 WO2005025623 A3 WO 2005025623A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytotoxic
- methods
- compositions
- protein
- delivering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compositions and methods are provided for delivering cytotoxic compounds, such as natural curcumoids and synthetic curcumin analogs, specifically to cancer cells and to blood vessels that nourish solid tumors. The compositions include a cytotoxic drug tethered to a protein, such as factor VIIa, which can bind with high affinity to a receptor, such as tissue factor, expressed on the surface of cancer cells and vascular endothelial cells within the tumor microenvironment. Upon binding, the drug-protein-receptor complex is endocytosed and the drug is subsequently liberated inside the target cell via proteolytic cleavage. The compositions and methods may increase the efficacy of the cytotoxic agets and decrease their side effects by delivering the agents to specific target cells, such as cancer cells, vascular endothelial cells in a tumor, and metastatic foci anywhere in the body, providing the target cells express surface bound tissue factor. Additionally, methods of synthesis of cytotoxic compound-protein conjugates are provided, for example, curcuminoid-tether-linker-factor VIIa composition, as well as pharmaceutically acceptable compositions and methods for delivering a therapeutically-effective amount of a cytotoxic compound-protein conjugate together with one or more pharmaceutically acceptable carriers (additives) and/or diluents to an animal or human patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49065603P | 2003-07-28 | 2003-07-28 | |
US60/490,656 | 2003-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005025623A2 WO2005025623A2 (en) | 2005-03-24 |
WO2005025623A3 true WO2005025623A3 (en) | 2005-12-22 |
Family
ID=34312158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/024490 WO2005025623A2 (en) | 2003-07-28 | 2004-07-28 | Ef-24-factor vii conjugates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005025623A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070270464A1 (en) * | 2006-02-24 | 2007-11-22 | Emory University | Prodrugs of curcumin analogs |
CN100425228C (en) * | 2006-08-04 | 2008-10-15 | 徐文凯 | Dispersion tablets and its prepn. method |
UA109633C2 (en) | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
NZ604718A (en) | 2010-06-15 | 2015-01-30 | Genmab As | Human antibody drug conjugates against tissue factor |
WO2014022660A1 (en) * | 2012-08-03 | 2014-02-06 | Georgia State University Research Foundation, Inc. | Curcumin analogs and methods of making and using thereof |
MX2016014826A (en) * | 2014-05-12 | 2017-09-28 | Haus Bioceuticals Inc | Curcumin-peptide conjugates and formulations thereof. |
CN106938051B (en) | 2016-08-22 | 2019-10-11 | 复旦大学 | Target the antibody-drug conjugates of tissue factor |
EP3762368B1 (en) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000201A1 (en) * | 1999-06-30 | 2001-01-04 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
WO2001002439A1 (en) * | 1999-07-01 | 2001-01-11 | Yale University | Neovascular-targeted immunoconjugates |
WO2001040188A1 (en) * | 1999-12-03 | 2001-06-07 | Emory University | Curcumin analogues for treating cancer |
WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
US20020168357A1 (en) * | 1997-03-10 | 2002-11-14 | Hing C. Wong | Antibodies for inhibiting blood coagulation and methods of use thereof |
WO2003075847A2 (en) * | 2002-03-08 | 2003-09-18 | Emory University | NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS |
WO2004007557A2 (en) * | 2002-07-12 | 2004-01-22 | Novo Nordisk A/S | Tf antagonist |
-
2004
- 2004-07-28 WO PCT/US2004/024490 patent/WO2005025623A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168357A1 (en) * | 1997-03-10 | 2002-11-14 | Hing C. Wong | Antibodies for inhibiting blood coagulation and methods of use thereof |
WO2001000201A1 (en) * | 1999-06-30 | 2001-01-04 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
WO2001002439A1 (en) * | 1999-07-01 | 2001-01-11 | Yale University | Neovascular-targeted immunoconjugates |
WO2001040188A1 (en) * | 1999-12-03 | 2001-06-07 | Emory University | Curcumin analogues for treating cancer |
WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
WO2003075847A2 (en) * | 2002-03-08 | 2003-09-18 | Emory University | NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS |
US20040009914A1 (en) * | 2002-03-08 | 2004-01-15 | Mamoru Shoji | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
WO2004007557A2 (en) * | 2002-07-12 | 2004-01-22 | Novo Nordisk A/S | Tf antagonist |
Also Published As
Publication number | Publication date |
---|---|
WO2005025623A2 (en) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Quiles et al. | Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy | |
BRPI0416028B8 (en) | compound, compound conjugates, pharmaceutical composition and conjugate uses | |
CA2910494C (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
WO2006113623A3 (en) | Elimination of heterogeneous or mixed cell population in tumors | |
WO2004013093A3 (en) | Cytotoxic agents containing novel potent taxanes and their therapeutic use | |
HK1155070A1 (en) | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders -cd70 - | |
CA2399866A1 (en) | Compositions and methods for treatment of angiogenesis in pathological lesions | |
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
WO2002060955A3 (en) | Modified antibodies and methods of use | |
WO2006096828A3 (en) | Chimeric proteins with phosphatidylserine binding domains | |
MXPA01011000A (en) | Conformationally restricted polyamine analogs as disease therapies. | |
WO1999048536A3 (en) | Delivery of long lasting therapeutic agents by forming covalent attachments in vivo | |
WO2005025623A3 (en) | Ef-24-factor vii conjugates | |
WO2005051315A3 (en) | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy | |
Kratz et al. | Antitumour activity of acid labile transferrin and albumin doxorubicin conjugates in in vitro and in vivo human tumour xenograft models | |
US9636419B2 (en) | Targeting multiple receptors on a cell surface for specific cell targeting | |
Yu et al. | A ferroptosis-inducing and leukemic cell-targeting drug nanocarrier formed by redox-responsive cysteine polymer for acute myeloid leukemia therapy | |
WO2004096159A3 (en) | Saposin c-dops: a novel anti-tumor agent | |
WO2005065361A3 (en) | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | |
Gaál et al. | Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide | |
TWI807320B (en) | Drug conjugates containing alpha-enolase antibodies and uses thereof | |
RU2326691C2 (en) | Urease application for malignant cells inhibition | |
WO2003075847A3 (en) | NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
CN112592406B (en) | Fixed-point conjugate of anti-CD 24 antibody and diethylazo-onium dialkoxide molecule and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |